ArticleCureus2025
Type I Cryoglobulinemia Associated With Multiple Myeloma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryoglobulinemia is a rare disorder characterized by the presence of serum cryoglobulins, which may result from clonal B-cell expansion (Type I), chronic infections, or autoimmune diseases (mixed cryoglobulinemia: Types II and III). We report the case of an 83-year-old man who fulfilled the diagnostic criteria for Type I cryoglobulinemic vasculitis, presenting with confluent purpuric macules and papules, some ulcerated, along with necrosis. Skin biopsy revealed thrombotic vasculopathy, and laboratory evaluation identified an IgG kappa light-chain monoclonal gammopathy, confirming multiple myeloma as the underlying etiology. Given its rarity and potential for severe complications, early and accurate diagnosis is crucial. In this case, targeted therapy for the underlying plasma cell disorder led to marked improvement of cutaneous lesions and resolution of hyperviscosity symptoms within two months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.